🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating around the world, with data suggesting more than 82 million new cases per year. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the context of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Public health authorities are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, was also approved in the same week. This medication, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This milestone represents a significant shift in the management of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Results and Worldwide Availability

As per findings published in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an comparable level with the current standard treatment, which involves a dual-drug approach. The trial enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in many low-income and middle-income countries.

Doctors directly involved have shared hope. Access to a single-dose, oral treatment of this kind is seen as a "revolutionary step" for public health efforts. This is deemed vital to lessen the impact of the illness for people and to stop the proliferation of untreatable gonorrhoea worldwide.